Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 7, 2011, Pages 1267-1273

  Force, Jeremy ^a   Rajan, Arun ^a   Dombi, Eva ^a   Steinberg, Seth M ^a   Giaccone, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Computed tomography; Non small cell lung cancer; RECIST; Three dimensional; Thymic cancer; Thymic malignancy; Thymoma; Volumetric

Indexed keywords

BELINOSTAT; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GOLD STANDARD; HUMAN; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; METASTATIC LUNG NON SMALL CELL CANCER; METASTATIC THYMUS CANCER; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; THYMUS CANCER; VOLUMETRIC RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; VOLUMETRY;

EID: 79959894126     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182199be2     Document Type: Article

References (20)

1. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva Albany, NY: World Health Organization; sold by WHO Publications Centre USA, WHO offset publication no. 48, 1979. Pp. 45.
2. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-214. (Pubitemid 11167383)
3. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
4. Bogaerts J, Ford R, Sargent D, et al. Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer 2009;45:248-260.
5. Rajan A, Giaccone G. Treatment of advanced thymoma and thymic carcinoma. Curr Treat Options Oncol 2008;9:277-287.
6. Huang J, Rizk NP, Travis WD, et al. Comparison of patterns of relapse in thymic carcinoma and thymoma. J Thorac Cardiovasc Surg 2009; 138:26-31.
7. Sorensen AG, Patel S, Harmath C, et al. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 2001;19: 551-557. (Pubitemid 32112870)
8. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15:257-260. (Pubitemid 38262625)
9. Nowak AK. CT, RECIST, and malignant pleural mesothelioma. Lung Cancer 2005;49(Suppl 1):S37-S40.
10. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009;361: 2221-2229.
11. Liu F, Zhao B, Krug LM, et al. Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer- aided volumetric measurement on computed tomography scans. J Thorac Oncol 2010;5:879-884.
12. Sohaib SA, Turner B, Hanson JA, et al. CT assessment of tumour response to treatment: Comparison of linear, cross-sectional and volumetric measures of tumour size. Br J Radiol 2000;73:1178-1184.
13. Solomon J, Warren K, Dombi E, et al. Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. Comput Med Imaging Graph 2004;28:257-265. (Pubitemid 38891818)
14. Pass HI, Temeck BK, Kranda K, et al. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998;115:310 -317; discussion 317-318.
15. Ferrari A, Miceli R, Meazza C, et al. Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. J Clin Oncol 2010;28:1322-1328.
16. Shah GD, Kesari S, Xu R, et al. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol 2006;8:38-46. (Pubitemid 43154449)
17. James K, Eisenhauer E, Christian M, et al. Measuring response in solid tumors: Unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999;91:523-528. (Pubitemid 29157060)
18. Ak G, Metintas M, Metintas S, et al. Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma. Eur J Radiol 2010;74:130-135.
19. Giaccone G, Rajan A, Carter C, et al. Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies. J Clin Oncol 2009;27(Suppl 15):7589.
20. Kelly RJ, Rajan A, Force J, et al. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced nonsmall cell lung cancer receiving Sorafenib. Clin Cancer Res 2011;17: 1190-1199.